Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bioregenx (BRGX) Shares Outstanding (Weighted Average) (2021 - 2025)

Bioregenx (BRGX) has 5 years of Shares Outstanding (Weighted Average) data on record, last reported at $959.1 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 3.26% year-over-year to $959.1 million; the TTM value through Sep 2025 reached $959.1 million, up 3.26%, while the annual FY2024 figure was $939.5 million, 46.85% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $959.1 million in Q3 2025 per BRGX's latest filing, roughly flat from $959.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $959.2 million in Q2 2025 and bottomed at $269.7 million in Q4 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $653.6 million, with a median of $700.9 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): changed 0.0% in 2022, then skyrocketed 182.49% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $269.7 million in 2021, then changed by 0.0% to $269.7 million in 2022, then skyrocketed by 137.18% to $639.8 million in 2023, then skyrocketed by 46.85% to $939.5 million in 2024, then grew by 2.08% to $959.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $959.1 million in Q3 2025, $959.2 million in Q2 2025, and $957.0 million in Q1 2025.